AMRN—As it turns out, the FDA delay in awarding NCE status did not end up harming AMRN insofar as the 30-month Hatch-Waxman stay on Paragraph-IV challenges runs until Jan 2020.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.